News

General News

Emyria Unveils Highest Potency CBD Capsule for FDA Pathway

April 24, 2023

Introducing EMD-RX9!

EMD-RX9 is a high-potency, highly bioavailable capsule aimed at becoming a prescription medication due to its capacity of more than 150mg of CBD.

“The higher dose strength and potency of EMD-RX9 will support Emyria’s US-focused registration programs by helping address the needs of patients requiring high CBD doses,” said Emyria (ASX:EMD) CEO Dr Michael Winlo.

EMD-RX9 will aim to enter Phase 1 clinical trials in the second half of 2023.

Emyria to Develop Psilocybin Therapy Care Model Study finds Medicinal Cannabis May Have Impact on Quality of Life

For Investors

November 23, 2023

Proactive Interview

November 21, 2023

New Independent Non-Executive Chairman

Have Questions?

If you have any question, please feel free to get in touch with us.